AzTrials
AzTrials

Moderate Acute MalnutritionNCT06305442

Microbiota Directed Food for Children With Moderate Acute Malnutrition

A study testing Microbiota-Directed Food and Ready-to-Use Supplementary Food in people with Moderate Acute Malnutrition, run by International Centre for Diarrhoeal Disease Research, Bangladesh at 1 site in Bangladesh.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Moderate acute malnutrition (MAM) refers to a condition characterized by a significant deficit in weight-for-length measurements in children aged 6 to 59 months. It is a crucial public health concern with detrimental effects on child growth, development, and overall well-being. Read more about this study

Who is it for?
Ages 6 to 24 months
Conditions the study is for
Moderate Acute Malnutrition
What is being tested?
Microbiota-Directed Food and Ready-to-Use Supplementary Food
Could I receive a placebo?
No, everyone receives an active treatment
How many people
230 participants
Where
1 siteBangladesh
Study dates
15 Apr 2024to 28 Feb 2026
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 6 to 24 months
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Parent(s) willing to sign consent form
  • Children aged 6-24 months
  • WLZ score <-2 to ≥-3 and/or MUAC ≥115 mm to <125 mm without bilateral pedal edema at the time of randomization

Who cannot join

  • Medical conditions: Malnourished children with complications requiring acute phase treatment in a hospital, children with tuberculosis or any chronic illness(es).
  • Any congenital/acquired disorder affecting growth, i.e., known case of trisomy-21 or cerebral palsy; children on an exclusion diet for the treatment of persistent diarrhea; having known history of soy, peanut or milk protein allergy
  • Severe anaemia (< 8 gm/dl)
  • Antibiotic use (within last 7 days before the onset of intervention)
  • Receiving concurrent treatment for another condition
  • children participating in other food intervention program

Trial locations and contacts

1 site in 1 country.

Ishita Mostafa, BDS, MPH contact

01755512359

ishita.mostafa@icddrb.org

Tahmeed Ahmed, MBBS, PhD contact

tahmeed@icddrb.org

Bangladesh1 site
  • Mirpur Study site

    Dhaka

    Dr. Jinat Alam, MPH, MBBS, +8801676742255, jinat.alam@icddrb.com

Other trials in Bangladesh

About this study

Official title: Efficacy of Microbiota-Directed Food in Children With Moderate Acute Malnutrition in Dhaka, Bangladesh

Moderate acute malnutrition (MAM) refers to a condition characterized by a significant deficit in weight-for-length measurements in children aged 6 to 59 months. It is a crucial public health concern with detrimental effects on child growth, development, and overall well-being. Addressing MAM is crucial to prevent its progression to severe acute malnutrition (SAM) and to ensure healthy child development. To meet the nutritional requirement of MAM children, icddr,b have come up with a novel intervention named microbiota-directed food (MDF), a ready-to-use supplementary food. The investigator propose this efficacy trial to establish the evidence on the effect of this novel intervention on ponderal growth, microbial and proteomic recovery among the children with MAM in comparison to the standard RUSF.

Read the detailed description

Burden: Moderate acute malnutrition (MAM) refers to a condition characterized by a significant deficit in weight-for-length measurements in children aged 6 to 59 months. It is a crucial public health concern with detrimental effects on child growth, development, and overall well-being. Addressing MAM is crucial to prevent its progression to severe acute malnutrition (SAM) and to ensure healthy child development. MAM affects a significant number of children globally, particularly in low- and middle-income countries where malnutrition is prevalent. According to the 2022 Bangladesh Demographic and Health Survey (2022 BDHS), 24% of children under the age of 5 are stunted, while 11% are wasted. The prevalence of worldwide MAM children is higher than that of children with SAM and 31.3 million under 5 children (~70%) was moderately wasted among all those children who were acutely malnourished in 2022. MAM children are found to be suffering from relative gut microbial immaturity, which is related to their growth faltering. Ready-to-use supplementary food (RUSF) is a key component of the outpatient treatment of MAM in community-based management. RUSF, being a ready-to-use food, does not require preparation or refrigeration and provides the necessary nutrients and energy for recovery from MAM.

Knowledge gap: Researchers at icddr,b in collaboration with Washington University in St. Louis, have developed a Microbiota-Directed Complementary Food (MDCF) formulation (based on locally available food ingredients) that has the potential to repair the gut microbiota of children with malnutrition. Results from a recently conducted study of MDCF on Bangladeshi children suffering from MAM showed that the children who received the food exhibited significantly faster rates of ponderal growth compared to those treated with a standard ready-to-use supplementary food (PR#18073). Early evidence, however, is limited to a small sample of children with MAM.

Relevance: To meet the nutritional requirement of MAM children, icddr,b have come up with a novel intervention named microbiota-directed food (MDF), a ready-to-use supplementary food by modifying the original MDCF recipe to meet the nutritional requirement of MAM children as well as to make it align with the existing WHO/UNICEF specifications for a nutritional intervention for treating acute malnutrition. The proposed formulation of MDF with adequate calorie content will improve the nutritional status by modulating and improving the gut microbial dysbiosis that is present in MAM children. Therefore, the investigator propose this efficacy trial to establish the evidence on the effect of this novel intervention on ponderal growth, microbial and proteomic recovery among the children with MAM in comparison to the standard RUSF.

Hypothesis (if any):

The locally developed MDF would be proven beneficial in nutritional recovery, repairing microbiota and restoring plasma biomarkers of healthy growth when compared to standard RUSF among children suffering from MAM.

Objectives:

Primary objectives:

•To assess the efficacy of MDF in improving the weight-for-length Z score (WLZ) of MAM children

Secondary:

  • To investigate the efficacy of MDF in repairing the microbiota of MAM children
  • To measure the efficacy of MDF in improving the Weight-for-Age Z-score (WAZ) in children with MAM
  • To measure the efficacy of MDF in improving the Length-for-Age Z-score (LAZ) in children with MAM
  • To explore and validate the impact of MDF supplement in restoring plasma and fecal biomarkers
  • To monitor the change produced by MDF in rebalancing the body composition (fat mass % and fat-free mass %)
  • To explore the efficacy of MDF in improving the cognitive, motor, and language function of MAM children

Methods:

Study Design: This study will be a double-blind, randomized controlled trial.

Participants: The trial will recruit 6-24-months-old children with Moderate Acute Malnutrition

Study Site: Bauniabadh and the adjacent slum area of Mirpur in Dhaka city.

Sample Size: 230; 2 arms; 115 per arm)

Intervention: Children in one arm will receive the MDF, and the children in the control arm will receive the conventional RUSF.

The children will receive intervention for 12 weeks with either the MDF or RUSF.

  • 6-24-months children with MAM - 12 weeks intervention with MDF + 12 weeks follow up
  • 6-24-months children with MAM - 12 weeks intervention with RUSF + 12 weeks follow up

Study Procedure Screening, and enrolment of study participants will be done in Bauniabadh and the adjacent slum area of Mirpur in Dhaka city. Initially 6-24-months-old children will be screened by the study health workers. Parents of eligible children who meet the inclusion criterion will be approached about enrolment into the study. A trained Field Research Assistant will explain the study in detail, answer any questions from the parent(s), and invite the parent(s) to enroll the child in the study. After acquiring consent from the parents, at the beginning of the study, information will be sought on the demographic characteristics (families' wealth, standard of housing, family structure, home environment, parental characteristics etc.). Morbidity data will be collected weekly during the intervention period, and biweekly in the follow-up phase.

In this study, nutritional status will be assessed through anthropometry, comparing with WHO growth reference standards. BIA is a method of assessing body composition by measuring body fat in relation to lean body mass. It is an integral part of a health and nutrition assessment. BIA will be used to measure total fat and fat-free mass before and after treatment. This non-invasive test simply involves the placement of electrodes on the person's hand and foot. A low-level, imperceptible electrical current is sent through the body. The flow of the current is affected by the amount of water in the body. The device measures how this signal is impeded through different types of tissue as it passes through the body and provides estimates of body water from which body fat is calculated.

A food frequency questionnaire will be used to collect data on Infant and Young Child Feeding (IYCF) practices. Food frequency data will be evaluated using the Minimum Acceptable Diet indicator as it meets standards for both minimum dietary diversity and minimum meal frequency.

The Bayley Scales of Infant and Toddler Development (BSID-IV) will be used to assess the early childhood development (cognitive, motor, and language development) before and after the intervention. The Caregiver Reported Early Development Instruments (CREDI) long form, developed by Harvard University, will also be used in this study (21).

Blood samples will be collected before, after the intervention/treatment, and at the end of the follow-up period for measuring haemoglobin, serum protein (total protein and albumin), thiamine, zinc, vitamin B12, vitamin D, and folate levels.

Non-diarrheal stool samples will be collected at enrolment, then monthly during the intervention and follow-up phase from all the participants for measuring biomarkers of gut inflammation and assessment of the composition of gut microbiota and features of the microbiome.

Oral swab samples will be collected by using commercial kit from each child at enrolment, after the intervention/treatment, and at the end of the follow-up period for measuring microbiota.

Being tested
Microbiota-Directed Food, Ready-to-Use Supplementary Food
Keywords
Microbiota Directed Food, Gut microbiota, MAM, Bangladesh

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Microbiota-Directed FoodDietary supplement

    Also called MDF

    MDF is a microbiota directed food for malnourished children aged 6 months and above. It is in sachet form. The sachet contains 92 gm of supplements and provides approximately 506 kcal.

  • Ready-to-Use Supplementary FoodDietary supplement

    Also called RUSF

    RUSF is standard ready-to-use supplementary food for MAM children aged 6 months and above.

Study groups in NCT06305442
Study groupRoleWhat they receive
Microbiota Directed Food (MDF)ExperimentalEach participant will receive 12 weeks of MDF supplement. After finishing the intervention phase, he/she will be followed-up for a 12-week period.
Receives: Dietary Supplement: Microbiota-Directed Food
Ready-to-Use Supplementary Food (RUSF)Active comparatorEach participant will receive 12 weeks of RUSF supplement. After finishing the intervention phase, he/she will be followed-up for a 12-week period.
Receives: Dietary Supplement: Ready-to-Use Supplementary Food

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Mean change in Weight-for-Length Z-score (WLZ)

    In this study, nutritional status will be assessed through anthropometric measurement before enrolment, then biweekly till completion of intervention and monthly during 12 weeks follow up.

    Measured: Baseline to 12 weeks of intervention followed by 12 weeks of follow-up

Secondary outcomes (6)
  1. Microbial community repair

    Non-diarrheal stool samples will be collected at enrolment, then monthly during the intervention and follow-up phase from all the participants for assessment of the composition of gut microbiota and features of the microbiome.

    Oral swab samples will be collected by using commercial kit from each child at enrolment, after the intervention/treatment, and at the end of the follow-up period for measuring microbiota.

    Measured: Baseline to 12 weeks of intervention followed by 12 weeks of follow-up

  2. Validated plasma and faecal biomarkers of health status (prioritized Luminex/ELISA panel including mediators of growth, systemic inflammation, gut inflammation/entero-pathogen burden)

    Blood samples will be collected before, after the intervention/treatment, and at the end of the follow-up period.

    Non-diarrheal stool samples will be collected at enrolment, then monthly during the intervention and follow-up phase from all the participants for measuring biomarkers of gut inflammation.

    Measured: Baseline to 12 weeks of intervention followed by 12 weeks of follow-up

  3. Mean change in Weight-for-Age Z-score (WAZ)

    In this study, nutritional status will be assessed through anthropometric measurement before enrolment, then biweekly till completion of intervention and monthly during 12 weeks follow up.

    Measured: Baseline to 12 weeks of intervention followed by 12 weeks of follow-up

  4. Mean change in Length-for-Age Z-score (LAZ)

    In this study, nutritional status will be assessed through anthropometric measurement before enrolment, then biweekly till completion of intervention and monthly during 12 weeks follow up.

    Measured: Baseline to 12 weeks of intervention followed by 12 weeks of follow-up

  5. Mean change in body composition (% body fat mass and % fat-free mass)

    In this study, nutritional status will be also assessed through Bioelectrical impedance at enrolment and after completion of intervention

    Measured: Baseline to 12 weeks of intervention

  6. Bayley Scales of early childhood development (cognitive, motor, language development)

    The Bayley Scales of Infant and Toddler Development (BSID-IV) will be used to assess the early childhood development (cognitive, motor, and language development) before and after the intervention. The Bayley-4 utilizes standard scores to assess a child's developmental progress compared to their age peers. Derived from individual raw scores, standard scores (with a mean of 100 and standard deviation of 15) offer a standardized metric for comparisons across Bayley-4 domains. The interpretation of standard scores on the Bayley-4 involves comparing an individual child's scores to the normative data provided in the test manual. Scores falling within one standard deviation (85-115) are considered within the average range, while scores below 85 in any domain may indicate potential developmental delays or concerns in that respective domain. Conversely, scores above 115 may suggest advanced development in that respective domain. Higher scores will mean better development.

    Measured: Baseline to 12 weeks of intervention

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Mar 2024
  2. Study start15 Apr 2024 (estimated)
  3. Primary completion31 Oct 2025 (estimated)
  4. Study completion28 Feb 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Double blind, randomized, parallel group, clinical trial
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
230 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06305442
Sponsor's protocol ID
PR-24031
Status last verified
Feb 2024
First submitted
5 Mar 2024
Last updated
24 Apr 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Microbiota-Directed Food and Ready-to-Use Supplementary Food in people with Moderate Acute Malnutrition, run by International Centre for Diarrhoeal Disease Research, Bangladesh at 1 site in Bangladesh.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 24 Apr 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Bangladesh. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Ishita Mostafa, BDS, MPH (01755512359, ishita.mostafa@icddrb.org), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Mean change in Weight-for-Length Z-score (WLZ) (time frame: Baseline to 12 weeks of intervention followed by 12 weeks of follow-up). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Apr 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in